In April 2026, FDA issued a warning letter to Purolea Cosmetics Lab after an inspection identified several CGMP violations. One section of the letter specifically addressed the company’s inappropriate use of artificial intelligence in pharmaceutical manufacturing. FDA stated that the firm used AI agents to help create drug product specifications, procedures, and master production or control records intended to comply with FDA requirements.
The problem was not that AI was used. The problem was that AI-generated documents were not adequately reviewed to ensure they were accurate and compliant. FDA explicitly stated that, when AI is used as an aid in document creation, the firm must review the AI-generated documents. FDA also noted that overreliance on AI was documented during the inspection.
One detail is particularly relevant for regulated teams. When FDA investigators raised the lack of required process validation, the firm reportedly responded that it was unaware of the legal requirement because the AI agent had not told them it was required.
For clinical trial organizations, the lesson is clear. AI may support drafting, review, summarization, or analysis. It does not carry regulatory responsibility. Qualified humans remain accountable for the decisions, documentation, and rationale.
Clinical trials operate under different expectations than everyday AI use. Outputs can affect patient safety, data integrity, trial conduct, submissions, and inspection outcomes.
For Clinical Operations, QA, Medical Monitoring, Central Monitoring, Data Management, and study leadership, the practical question is no longer whether AI will be used. It is whether teams know how to use it within controlled boundaries.
| AI use must be | What this means in practice |
|---|---|
| Approved | Teams know which tools may be used |
| Fit for purpose | AI is used only for appropriate tasks |
| Reviewed | Outputs are verified by qualified people |
| Documented | Use, rationale, and review can be reconstructed |
| Accountable | Final decisions remain with humans |
The warning letter should not be read as an argument against AI. It should be read as a warning against uncontrolled reliance.
Common risk patterns include:
These are capability issues as much as technology issues.
This is not a single case. FDA and EMA are aligning on one principle: AI must be used with transparency, validation, and human accountability.
This is not a single case. FDA and EMA are aligning on one principle: AI must be used with transparency, validation, and human accountability.
Define the intended use
Clarify what AI is being used for and whether that use is permitted.
Confirm the tool and environment
Use only approved, secure, and appropriate systems.
Assess the risk
Consider impact on patient safety, data integrity, confidentiality, blinding, and regulatory decisions.
Document when required
Record the tool, purpose, review, and final human decision where the impact requires traceability.
Review the output
Treat AI output as draft support, not verified evidence.
GCP-compliant AI capability is not only about knowing how to prompt a system. Teams need to understand where AI fits, where it creates risk, and where human accountability must remain visible.
A useful AI capability baseline should cover:
AI can accelerate regulated work, but it cannot absorb regulated responsibility.
For clinical trial teams, the defensible position is not “the AI gave us the answer.”
The defensible position is: “We used an approved tool for an appropriate purpose, reviewed the output, documented the rationale, and retained human accountability.”
That is why AI capability training is becoming essential for clinical research organizations.
MyRBQM® Academy’s AI Essentials for Clinical Trials (GCP-Compliant) eCourse helps clinical teams understand how AI can be used responsibly in GCP-regulated environments.
It is designed for professionals in Clinical Operations, QA, Data, Central Monitoring, Medical Monitoring, and study leadership who need a practical baseline before AI use becomes broader, faster, or harder to control.
Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.
In modern clinical trials complexity continues to rise — data volumes grow, endpoints broaden, and decentralized elements become the norm. Under ICH E6(R3), sponsors are expected to move from reactive monitoring to oversight that is anticipatory and risk-based. Predictive analytics enables that shift.
When oversight teams wait for problems to appear — delayed AE reporting, slow site performance, patient drop-out patterns — the cost of correction rises. Predictive analytics lets trial teams detect trends before they become crises: subtle shifts become visible, and intervention windows widen.
Metrics such as query rates, lab turnaround times, visit reschedules and enrollment trends are analysed over time. The algorithm identifies and forecasts “what if” scenarios: if current patterns continue, what is likely to happen next?
This practical capability aligns with E6(R3)’s requirement to document risk-based monitoring logic, decision rationale and corrective action pathways.
A site begins to show a consistent five-day drift in AE submissions. On its own this may not raise an alert. Predictive modelling shows that if the delay trend reaches ten days in two weeks, safety review time will be compromised. The oversight lead contacts the site, uncovers a staffing issue and re-allocates monitoring resources — preventing escalation.This practical capability aligns with E6(R3)’s requirement to document risk-based monitoring logic, decision rationale and corrective action pathways.
Predictive analytics does not replace the clinical or operational decision-maker. It guides where to look, when to act, and how to allocate resources — enabling oversight teams to focus on exception rather than every datapoint.
Predictive oversight elevates operational efficiency, enhances participant safety windows and meets regulatory expectations for traceable risk-based decision-making. It’s not about automating judgment — it amplifies it.
Need a quote, speaker, or more info about Cyntegrity? Reach out directly to our media contact for timely assistance.
Industry Solutions
Featured Insights
Start Your Roll-Out
RBQM Capability Pathway
Quick Answers
Presented By
Dr. Artem Andrianov
Cyntegrity
Presented By
Shehnaz Vakharia
ADAMAS Consulting
From retrospective QA → to continuous, data-driven oversight
Date
April, 27th 2026
